Patents by Inventor John J. Miglietta

John J. Miglietta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-BAFF antibodies
    Patent number: 11370818
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 28, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • NOVEL ANTI-BAFF ANTIBODIES
    Publication number: 20190309034
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 10, 2019
    Inventors: Scott Ronald BRODEUR, Keith A. CANADA, Michael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John J. MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang XIAO
  • Anti-BAFF antibodies
    Patent number: 10377804
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: August 13, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • NOVEL ANTI-BAFF ANTIBODIES
    Publication number: 20180127474
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: November 6, 2017
    Publication date: May 10, 2018
    Inventors: Scott Ronald BRODEUR, Keith A. CANADA, Michael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John J. MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang XIAO
  • Antibodies specific for CD44v6
    Patent number: 7417127
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: August 26, 2008
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Bohringer Ingelheim International GmbH
    Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
  • Antibodies specific for CD44v6
    Patent number: 6972324
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: December 6, 2005
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International, GmbH
    Inventors: Günther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
  • Antibodies specific for CD44v6
    Publication number: 20030190319
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Application
    Filed: May 20, 2002
    Publication date: October 9, 2003
    Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen